Across 57 Phase III cell therapy records, European activity is concentrated in a small set of high-repeat hospital networks. Hospital Universitari Vall d’Hebron is the leading named site with 13 site participations, followed by Centre Hospitalier Universitaire de Lille with 12. Oncology dominates the high-volume site pattern, especially multiple myeloma and B-cell malignancy programs.
The top 10 named sites account for 81 site participations. Spain, France, Germany, and Italy dominate this leadership tier, reflecting the concentration of advanced cell therapy infrastructure in large oncology and haematology centers.
The leading sites are not isolated high-enrolling centers; they are repeat participants across multiple disease areas, especially haematology-oncology cell therapy programs.
Country-level participation is led by the large EU5 oncology networks. The strongest recurring country signals are Spain, Germany, France, Italy, and the Netherlands, which together anchor most of the high-repeat site list and the largest planned-patient allocations.
Spain, Germany, and France provide the broadest site footprint, while the Netherlands shows a stronger patient-allocation signal in selected later records, including pancreatic cancer and myeloma programs.
Among oncology records, multiple myeloma is the dominant disease group, followed by B-cell lymphoma / B-cell leukemia programs. Solid tumor cell therapy appears, but with fewer repeat sites and more concentrated country allocation.
The Phase III cell therapy landscape remains haematology-heavy. Multiple myeloma and B-cell malignancies drive most repeat participation, while solid tumor programs are more selective and site-concentrated.
The cohort includes 34 records in 2024, 16 in 2025, and 7 in 2026. 2024 therefore represents 34/57 records, or 59.6% of the analyzed Phase III cell therapy cohort.